Premium
Analysis and comparison of the cost‐effectiveness of statins according to the baseline low‐density lipoprotein cholesterol level in Korea
Author(s) -
Jeong Y. J.,
Kim H.,
Baik S. J.,
Kim T. M.,
Yang S. J.,
Lee S.H.,
Cho J.H.,
Lee H.,
Yim H. W.,
Choi I. Y.,
Yoon K.H.,
Kim H.S.
Publication year - 2017
Publication title -
journal of clinical pharmacy and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.622
H-Index - 73
eISSN - 1365-2710
pISSN - 0269-4727
DOI - 10.1111/jcpt.12512
Subject(s) - rosuvastatin , atorvastatin , pravastatin , pitavastatin , medicine , simvastatin , statin , cholesterol , ldl cholesterol , pharmacology , gastroenterology
Summary What is known and objective There are a few Korean studies on the economics of statins based on reduction in low‐density lipoprotein cholesterol ( LDL ‐C) data from other countries. This study aimed to analyse and compare the cost‐effectiveness of statins according to the baseline LDL ‐C level in Korea. Methods Between January 2009 and December 2015, the data of patients who were prescribed statins for the first time were extracted from electronic medical records. We performed a cost‐effectiveness analysis ( CEA ) based on the LDL ‐C reduction rate ( CEA ‐ RR ) and target achievement rate. Results and discussion Among high‐intensity statins, the CEA ‐ RR value of rosuvastatin (20 mg) was significantly lower than that of atorvastatin (40 mg) at all baseline LDL ‐C levels, except levels of 160–189 mg/ dL . Additionally, at baseline LDL ‐C levels of 130–159 mg/ dL , the CEA ‐ RR value of rosuvastatin (20 mg) was three times lower than that of atorvastatin (40 mg) (9·1 ± 2·5 $/% vs. 31·7 ± 15·0 $/%, P < 0·001). Among moderate‐to‐low‐intensity statins, rosuvastatin (5 mg) showed the lowest CEA ‐ RR value (4·0 ± 0·6 $/%), and the value significantly increased for pitavastatin (2 mg) (8·0 ± 0·6 $/%), atorvastatin (10 mg) (9·5 ± 0·5 $/%), simvastatin (10·8 ± 1·1 $/%) and pravastatin (40 mg) (11·5 ± 0·9 $/%) in order ( P < 0·0001). On changing from atorvastatin (10 mg) to atorvastatin (20 mg), the additional yearly cost was 16·0 and additional CEA ‐ RR value was 2·74 $/%. On the other hand, on changing from atorvastatin (10 mg) to rosuvastatin (10 mg), the additional yearly cost was −16·3 and additional CEA ‐ RR value was −1·8 $ / %. What is new and conclusion We successfully compared the cost‐effectiveness of statins according to the baseline LDL ‐C level in Korea. It is expected that our findings will help clinical decision‐making with regard to statin prescription, and this will help reduce national medical expenditure.